Moayeri H, Sokal J E
Am J Med. 1979 May;66(5):773-8. doi: 10.1016/0002-9343(79)91115-x.
Among 60 patients with chronic lymphocytic leukemia, higher in vitro uptake of tritiated (3H) thymidine by leukocytes of a standard volume of peripheral blood was associated with a higher lymphocyte count, a more advanced stage, greater frequency of functional impairment and shorter survival. Appropriate analyses demonstrated that leukocyte thymidine uptake correlated with survival independently of these other disease features. Relative thymidine uptake (radioactivity per 10(3) lymphocytes) did not prove to be a useful prognostic parameter. Among 33 patients not receiving antileukemic therapy at the time of study, 15 of 17 (88 per cent) of those with higher thymidine uptake values, but only 3 of 16 (19 per cent) of those with lower values, were treated during a median follow-up period of four and a half years (p less than 0.001). Seven of the former group, but none of the latter group, died during the first three years of follow-up (p less than 0.01). We conclude that thymidine uptake by circulating leukocytes constitutes a relatively accurate index of the proliferating leukemic cell mass in this disease and provides useful prognostic information.
在60例慢性淋巴细胞白血病患者中，标准体积外周血白细胞对氚标记（3H）胸腺嘧啶核苷的体外摄取量较高与淋巴细胞计数较高、疾病分期较晚、功能损害频率较高以及生存期较短相关。适当的分析表明，白细胞胸腺嘧啶核苷摄取量与生存期相关，独立于这些其他疾病特征。相对胸腺嘧啶核苷摄取量（每10³个淋巴细胞的放射性）并非一个有用的预后参数。在研究时未接受抗白血病治疗的33例患者中，在中位随访期4.5年期间，胸腺嘧啶核苷摄取量较高的患者中17例有15例（88%）接受了治疗，而摄取量较低的患者中16例仅有3例（19%）接受了治疗（p<0.001）。前一组中有7例在随访的前三年死亡，而后一组中无一例死亡（p<0.01）。我们得出结论，循环白细胞对胸腺嘧啶核苷的摄取构成了该疾病中白血病细胞增殖量的一个相对准确的指标，并提供了有用的预后信息。
